Nexalin Technology, Inc. announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device, has been granted regulatory approval by the Sultanate of Oman?s Ministry of Health.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7444 USD | +8.67% | +2.76% | +83.89% |
1st Jan change | Capi. | |
---|---|---|
+83.89% | 5.54M | |
+9.24% | 221B | |
+15.84% | 198B | |
+23.95% | 148B | |
+31.67% | 112B | |
+4.37% | 66.85B | |
+14.99% | 52.84B | |
+4.85% | 50.86B | |
-4.47% | 38.75B | |
-0.41% | 35.15B |
- Stock Market
- Equities
- NXL Stock
- News Nexalin Technology, Inc.
- Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device